Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS5677177 A
Publication typeGrant
Application numberUS 08/486,409
Publication dateOct 14, 1997
Filing dateJun 7, 1995
Priority dateMar 8, 1991
Fee statusPaid
Also published asUS5654182, US5885836, US6956146, US7371577, US20020166138, US20050257276, WO1992015694A1
Publication number08486409, 486409, US 5677177 A, US 5677177A, US-A-5677177, US5677177 A, US5677177A
InventorsGeoffrey M. Wahl, Stephen V. O'Gorman
Original AssigneeThe Salk Institute For Biological Studies
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
FLP-mediated gene modification in mammalian cells, and compositions and cells useful therefor
US 5677177 A
Abstract
A gene activation/inactivation and site-specific integration system has been developed for mammalian cells. The invention system is based on the recombination of transfected sequences by FLP, a recombinase derived from Saccharomyces. In several cell lines, FLP has been shown to rapidly and precisely recombine copies of its specific target sequence. For example, a chromosomally integrated, silent β-galactosidase reporter gene was activated for expression by FLP-mediated removal of intervening sequences to generate clones of marked cells. Alternatively, the reverse reaction can be used to target transfected DNA to specific chromosomal sites. These results demonstrate that FLP can be used, for example, to mosaically activate or inactivate transgenes for a variety of therapeutic purposes, as well as for analysis of vertebriate development.
Images(3)
Previous page
Next page
Claims(24)
That which is claimed is:
1. A composition that effects recombination in mammalian cells comprising:
(i) an isolated and purified FLP recombinase, or an isolated and purified nucleotide sequence encoding same, and
(ii) a first DNA comprising a nucleotide sequence containing a first FLP recombination target site (FRT) therein,
wherein the genome of the mammalian cells contains a stably integrated second FRT site, and wherein said FLP recombinase catalyzes recombination between said first FRT and the second FRT, thereby precisely targeting integration of said first DNA into the genome.
2. A composition according to claim 1, wherein said first DNA comprises at least a first segment of a first gent of interest, said composition further comprising:
(iii) a second DNA comprising:
(a) at least a second segment of said first gene of interest, or
(b) at least a segment of a second gent of interest; wherein said second DNA contains at least one FLP recombination target site; and wherein said second DNA, when combined in reading frame with said first DNA, provides a functional gene.
3. A composition according to claim 2 wherein said second DNA comprises said second segment of said first gene of interest.
4. A composition according to claim 2 wherein said second DNA comprises said segment of said second gene of interest.
5. A composition according to claim 4 wherein said segment of said second gene of interest, when combined in reading frame with said first DNA, provides a hybrid, functional gene.
6. A composition according to claim 4 wherein said segment of said second gene of interest, when combined with said first DNA, disrupts the function of said first gene of interest.
7. A composition according to claim 1 wherein said first DNA further comprises a third FRT.
8. A composition according to claim 1 wherein said FLP recombinase is from a species of the genus Saccharomyces.
9. A composition according to claim 1 wherein said FLP recombinase is from a strain of Saccharomyces cerevisiae.
10. A composition according to claim 9 wherein said FLP recombinase is encoded by the sequence set forth as SEQ ID NO:1.
11. A composition according to claim 1 wherein said first DNA provides a readily analyzable marker upon expression.
12. A composition according to claim 2 wherein said second DNA provides a readily analyzable marker upon expression.
13. A composition according to claim 1 wherein said first DNA is an autonomous fragment comprising:
(a) said first FRT,
(b) at least one restriction endonuclease recognition site,
(c) at least one marker gene,
(d) a bacterial origin of replication, and optionally
(e) a mammalian cellular or vital origin of DNA replication.
14. A DNA construct comprising, as an autonomous fragment, in the following order, reading from 5' to 3' along said fragment:
(a) a first FLP recombination target site,
(b) an insert segment comprising:
(1) at least one restriction endonuclease recognition site,
(2) at least one marker gene,
(3) a bacterial origin of replication, and optionally
(4) a mammalian cellular or viral origin of DNA replication, and
(c) a second FLP recombination target site in tandem with said first FLP recombination target site.
15. A method for the assembly of functional gene(s) for expression in mammalian cells, by recombination of individual inactive gene segments from one or more gene(s) of interest, wherein each of said segments contains at least one FRT, said method comprising:
contacting said individual inactive gene segments with a FLP recombinase, under conditions suitable for recombination to occur, thereby providing upon recombination a DNA which encodes a functional gene of interest, the expression product of which is biologically active.
16. A method according to claim 15 wherein said FLP recombinase is from a species of the genus Saccharomyces.
17. A method according to claim 15 wherein said FLP recombinase is from a strain of Saccharomyces cerevisiae.
18. A method according to claim 17 wherein said FLP recombinase is encoded by the sequence set forth as SEQ ID NO:1.
19. An isolated mammalian cell, Wherein the genomic DNA of said cell contains an inserted heterologous first DNA comprising at least one FLP recombination target site therein.
20. An isolated mammalian cell according to claim 19 wherein said first DNA comprises at least a first segment of one or more first gene(s) of interest.
21. An isolated mammalian cell according to claim 20, further comprising DNA encoding, and capable of expressing, in said cell, a FLP recombinase.
22. An isolated mammalian cell according to claim 20 wherein said first gene(s) of interest provide a readily analyzable marker feature upon expression.
23. An isolated mammalian cell according to claim 19 wherein said FLP recombination target site has the sequence:
5'-GAAGTTCCTATTCTCTAGAAAGTATAGGAACTTC-3'.
24. An isolated mammalian cell according to claim 20 further comprising a second DNA, wherein said second DNA comprises:
(a) at least a second segment of said first gene of interest, or
(b) at least a segment of a second gene of interest;
wherein said second DNA contains at least one FLP recombination target site; and wherein said second DNA, when combined in reading frame with said first DNA, provides a functional gene.
Description

This application is a divisional application of U.S. Ser. No. 08/147,912, filed Nov. 3, 1993, now pending, which is in turn a continuation application of U.S. Ser. No. 07/666,252, filed Mar. 8, 1991, now abandoned, the entire contents of each of which are hereby incorporated by reference herein.

This invention relates to recombinant DNA technology. In a particular aspect, this invention relates to methods for the site-specific recombination of DNA in mammalian cells or host mammalian organisms. In another aspect, the present invention relates to novel DNA constructs, as well as compositions, cells and host organisms containing such constructs. In yet another aspect, the present invention relates to methods for the activation and/or inactivation of expression of functional genes. In a further aspect, the present invention relates to methods for the introduction of DNA into specific sites in the genome of mammalian cells. In a still further aspect, the present invention relates to gene therapy methods. In still another aspect, the present invention relates to means for the recovery of transfected DNA from a cell or host organism. In a still further aspect, the present invention relates to assay methods.

BACKGROUND OF THE INVENTION

Many recent manipulations of gene expression involve the introduction of transfected genes (transgenes) to confer some novel property upon, or to alter some intrinsic property of, mammalian cells or organisms. The efficacy of such manipulations is often impaired by such problems as the inability to control the chromosomal site of transgene integration; or the inability to control the number of copies of a transgene that integrate at the desired chromosomal site; or by difficulties in controlling the level, temporal characteristics, or tissue distribution of transgene expression; or by the difficulty of modifying the structure of transgenes once they are integrated into mammalian chromosomes.

Transgenes are often introduced into mammalian cells or organisms to determine which components of a transgene are required for specific qualitative or quantitative alterations of the host system. Since both chromosomal position and copy number are major determinants of transgene function, the usefulness of these analyses is limited because current techniques for efficiently introducing transgenes into mammalian hosts result in the insertion of a variable number of transgene copies at random chromosomal positions. It is, therefore, difficult (if not impossible) to compare the effects of one transgene to those of another if the two transgenes occupy different chromosomal positions and are present in the genome at different copy numbers. Considerably more refined analyses would be possible if one could routinely introduce single copies of a variety of transgenes into a defined chromosomal position.

The spatial or temporal characteristics of transgene expression is difficult to control in intact organisms. The restricted expression of transgenes is potentially of great interest, as this technique can be employed for a variety of therapeutic applications, e.g., for the selective interruption of a defective gene, for the alteration of expression of a gene which is otherwise over-expressed or under-expressed, for the selective introduction of a gene whose product is desirable in the host, for the selective removal or disruption of a gene whose expression is no longer desired in the host, and the like.

Transgene expression is typically governed by a single set of control sequences, including promoters and enhancers which are physically linked to the transgenes (i.e., cis-acting sequences). Considerably greater expression control could be achieved if transgene expression could be placed under the binary control of these cis-acting sequences, plus an additional set of sequences that were not physically linked to the transgenes (i.e., trans-acting sequences). A further advantage would be realized if the transient activity of these trans-acting functions resulted in a stable alteration in transgene expression. In this manner, it would be possible, for example, to introduce into a host a transgene whose expression would have lethal or deleterious effects if it was constitutively expressed in all cells. This would be accomplished by delaying the expression of the transgene to a specific time or developmental stage of interest, or by restricting the expression of the transgene to a specific subset of the cell population.

It is currently difficult (if not impossible) to precisely modify the structure of transgenes once they have been introduced into mammalian cells. In many applications of transgene technology, it would be desirable to introduce the transgene in one form, and to then be able to modify the transgene in a defined manner. By this means, transgenes could be activated or inactivated or the sequences which control transgene expression could be altered by either removing sequences present in the original transgene or by inserting additional sequences into the transgene.

Previous descriptions of recombinase-mediated rearrangement of chromosomal sequences in Drosophila and mammalian cells have not directly addressed the question of whether site-specific recombinases could routinely create a functional translational reading frame. Moreover, the reported efficiency of the prior art recombinase system, in the only other description of site-specific recombination in mammalian cells reported to date based on Cre recombinase, described by Sauer and Henderson in Nucleic Acids Research, Vol. 17: 147 (1989)! appears to be quite low.

BRIEF DESCRIPTION OF THE INVENTION

In accordance with the present invention, we have developed a system for the selective modification of chromosomal or extrachromosomal DNA in mammalian cells. Selective modification can involve the insertion of one DNA into another DNA (e.g., to create a hybrid gene, to activate a gene, to inactivate a gene, and the like), or the removal of specific DNA molecule(s) from other DNA molecule(s) containing the DNA to be removed (e.g., to inactivate a gene, to bring desired DNA fragments into association with one another, and the like).

The recombination system of the present invention is based on site-specific recombinase, FLP. In one application of the invention recombination system, FLP-mediated removal of intervening sequences is required for the formation of a functional gene. Expression of the functional gene therefore, falls under the control of both the regulatory sequences associated with the functional gene and also under the control of those sequences which direct FLP expression.

The reverse of the above-described process, i.e., the FLP-mediated introduction of DNA, provides a convenient and selective means to introduce DNA into specific sites in mammalian chromosomes.

FLP-mediated recombination of marker genes provides a means to follow the fate of various sequences over the course of development and/or from generation-to-generation. The recombination event creates a functional marker gene. This gain-of-function system can be used for lineage analyses in a wide variety of tissues in different organisms. Prior to FLP-mediated recombination, the marker gene is normally silent, i.e., the phenotype typical of the marker is not observed. In the absence of FLP, spontaneous recombination to produce functional marker occurs only at very low frequencies. In the presence of FLP, functional marker is efficiently produced. In addition, this gain-of-function system is heritable and is easily detected by simple histochemical assays. For example, in transgenic mice, the lineages in which recombination is to occur can be controlled by appropriate selection of the promoters used to drive FLP expression. This could include promoters that are only transiently active at a developmental stage that substantially precedes overt cell differentiation. Since transcription of the marker gene is controlled by regulatory sequences associated therewith, functional marker genes can be expressed at later developmental stages, after cell differentiation has occurred. By this means, it is possible to construct a map for mammalian development that correlates embryonic patterns of gene expression with the organization of mature tissues.

BRIEF DESCRIPTION OF THE FIGURES

FIGS. 1A and 1B. FIG. 1 presents schematic diagrams of FLP-mediated recombination events. In FIG. 1A, FLP-mediated introduction of DNA is illustrated, while in FIG. 1B, FLP-mediated removal of intervening sequences is illustrated.

FIGS. 2A, 2B, and 2C. FIG. 2 is presented in three parts. FIG. 2A presents schematic diagrams of the expression vectors pFRTβGAL, pNEOβGAL, and pOG44 FLP. FIG. 2B presents a Southern blot of Hirt lysates prepared from 293 (human embryonic kidney) cells transfected with one microgram of pNEOβGAL and varying amounts of the pOG44 FLP expression vector. FIG. 2C graphically presents the β-galactosidase activities in the same transfections shown in part B, referred to above.

FIGS. 3A and 3B. FIG. 3A, at the top, presents a schematic of the pattern of plasmid integration in E25 deduced from Southern blot analysis. FIG. 3A, in the middle, presents the predicted pattern for β-galactosidase positive subclones of E25 if precise recombination across the FLP-recombination target sites occurs. FIG. 3A, at the bottom, presents the predicted pattern for β-galactosidase negative, neomycin resistant subclones of E25B2 after FLP mediated insertion of pOG45. FIG. 3B presents an analysis of genomic DNA from a cell line with a single integrated copy of pNEOβGAL (i.e., CVNEOβGAL/E25, designated as E25), two derivative β-galactosidase-positive subclones (designated as E25B1 and E25B2), and two subclones derived from E25B2 after transfection with pOG45 (designated as B2N1 and B2N2).

DETAILED DESCRIPTION OF THE INVENTION

In accordance with the present invention, there is provided a mammalian recombination system comprising:

(i) FLP recombinase, or a nucleotide sequence encoding same, and

(ii) a first DNA comprising a nucleotide sequence containing at least one FLP recombination target site.

In accordance with another embodiment of the present invention, there are provided novel DNA constructs useful for the introduction of DNA into the genome of a transfected organism, said DNA construct comprising, as an autonomous fragment:

(a) at least one FLP recombination target site,

(b) at least one restriction endonuclease recognition site,

(c) at least one marker gene,

(d) a bacterial origin of replication, and optionally

(e) a mammalian cellular or viral origin of DNA replication.

In accordance with yet another embodiment of the present invention, there are provided novel DNA constructs useful for the rescue of DNA from the genome of a transfected organism, said DNA construct comprising, as an autonomous fragment, in the following order, reading from 5' to 3' along said fragment:

(a) a first FLP recombination target site,

(b) an insert portion comprising, in any suitable sequence:

(1) at least one restriction endonuclease recognition site,

(2) at least one marker gene,

(3) a bacterial origin of replication, and optionally

(4) a mammalian cellular or viral origin of DNA replication, and

(c) a second FLP recombination target site in tandem with said first FLP recombination target site.

In addition, there are provided methods for the recovery of transfected DNA from the genome of a transfected organism employing the above-described constructs.

In accordance with still another embodiment of the present invention, there is provided a method for the assembly of a functional gene (which is then suitable for activation of expression), in mammalian cells, by recombination of individually inactive gene segments derived from one or more gene(s) of interest, wherein each of said segments contains at least one recombination target site, said method comprising: contacting said individually inactive gene segments with a FLP recombinase, under conditions suitable for recombination to occur, thereby providing a DNA sequence which encodes a functional gene of interest.

In accordance with a further embodiment of the present invention, there is provided a method for the disruption of functional gene(s) of interest, thereby inactivating expression of such gene(s), in mammalian cells, wherein said gene(s) of interest contain at least one FLP recombination target site, said method comprising contacting said gene(s) of interest with:

(i) a DNA segment which contains at least one FLP recombination target site, and

(ii) FLP recombinase;

wherein said contacting is carried out under conditions suitable for recombination to occur between said gene and said DNA segment, thereby disrupting the gene(s) of interest and rendering said gene(s) non-functional.

In accordance with a still further embodiment of the present invention, there is provided a method for the precisely targeted integration of DNA into the genome of a host organism, said method comprising:

(i) introducing a FLP recombination target site into the genome of cells which are compatible with the cells of the subject,

(ii) introducing a first DNA comprising a nucleotide sequence containing at least one FLP recombination target site therein into the FLP recombination target site in the genome of said cells by contacting said cells with said first DNA and FLP recombinase, and thereafter

(iii) introducing the cells produced by the process of step (ii) into said subject, wherein the resulting cells and/or organism have the optional ability to have DNA reproducibly and repetitively inserted into and/or recovered from the host cells and/or organism.

In accordance with another aspect of the present invention, there are provided mammalian cells, wherein the genomic DNA of said cells contain at least one FLP recombination target site therein.

In accordance with yet another aspect of the present invention, there are provided transgenic, non-human mammals, wherein said mammals contain at least one FLP recombination target site in the genomic DNA thereof.

In accordance with yet another aspect of the present invention, there is provided a method for the site-specific integration of transfected DNA into the genome of the above-described cells and/or transgenic, non-human mammals, said method comprising:

(i) contacting said genome with:

(a) FLP recombinase, and

(b) a first DNA comprising a nucleotide sequence containing at least one FLP recombination target site therein; and thereafter

(ii) maintaining the product of Step (i) under conditions suitable for site-specific integration of said DNA sequence to occur at the FLP recombination target site in said genome.

In accordance with a further aspect of the present invention, there is provided a method for the analysis of the development of a mammal, said method comprising:

(a) providing a transgenic mammal comprising:

(i) an expression construct encoding FLP under the control of a conditional promoter, and

(ii) a reporter construct under the control of the same or a different promoter, wherein said reporter construct encodes a functional or non-functional reporter gene product, and wherein said construct contains at least one FLP recombination target site therein,

wherein the functional expression of the functional reporter gene is disrupted when said FLP recombination event occurs, or

wherein the functional expression of the non-functional reporter gene commences when said FLP recombination event occurs; and

(b) following the development of said mammal to determine when expression of functional reporter gene product either commences or is disrupted.

In accordance with a still further aspect of the present invention, there is provided a co-transfection assay FLP-mediated recombination, said assay comprising:

(a) co-transfecting a host mammalian cell with:

(i) a FLP expression plasmid, and

(ii) a reporter plasmid comprising a reporter gene inactivated by the presence of at least one recombination target site; and

(b) monitoring said host cell under a variety of conditions for the gain of expression of functional reporter gene product.

FLP recombinase is a protein which catalyzes a site-specific recombination reaction that is involved in amplifying the copy number of the 2μ plasmid of S. cerevisiae during DNA replication. FLP protein has been cloned and expressed in E. coli see, for example, Cox, in proceedings of the National Academy of Sciences U.S.A., Vol. 80: 4223-4227 (1983)!, and has been purified to near homogeneity see, for example, Meyer-Lean, et al., in Nucleic Acids Research, Vol. 15: 6469-6488 (1987)!. FLP recombinases contemplated for use in the practice of the present invention are derived from species of the genus Saccharomyces. Preferred recombinases employed in the practice of the present invention are derived from strains of Saccharomyces cerevisiae. Especially preferred recombinases employed in the practice of the present invention are proteins having substantially the same amino acid sequence as set forth in Sequence I.D. No. 2, as encoded, for example, by Sequence I.D. No. 1, or the sequence set forth by Hartley and Donelson, Nature 286: 860 (1980).

The FLP recombination target site (sometimes referred to herein as "FRT") has also been identified as minimally comprising two 13 base-pair repeats, separated by an 8 base-pair spacer, as follows: ##STR1## The nucleotides in the above "spacer" region can be replaced with any other combination of nucleotides, so long as the two 13 base-pair repeats are separated by 8 nucleotides. The actual nucleotide sequence of the spacer is not critical, although those of skill in the art recognize that, for some applications, it is desirable for the spacer to be asymmetric, while for other applications, a symmetrical spacer can be employed. Generally, the spacers of the FLP recombination target sites undergoing recombination with one another will be the same.

As schematically illustrated in FIG. 1A, contact of genomic DNA containing a FLP recombination target site (shown as the linear Psv-BETA-GAL construct) with a vector containing a FLP recombination target site, in the presence of the protein, FLP recombinase, results in recombination that forms a new genomic sequence wherein the vector sequences have been precisely incorporated into the genome of the host. The reverse of this process is shown schematically in FIG. 1B, wherein a genomic sequence or construct containing two tandemly oriented FLP recombination target sites, upon contacting with FLP, is recombined and the FLP recombination target site-bounded fragment is excised as a circular molecule.

Genes of interest contemplated for use in the practice of the present invention can be selected from genes which provide a readily analyzable functional feature to the host cell and/or organism, e.g., visible markers (such as β-galactosidase, thymidine kinase, tyrosinase, and the like), selectable markers, (such as markers useful for positive and negative selection, e.g., genes for antibiotic resistance), as well as other functions which alter the phenotype of the recipient cells, and the like.

The first DNA employed in the practice of the present invention can comprise any nucleotide sequence containing at least one FLP recombination target site, which will precisely define the locus at which FLP-mediated recombination will occur. The nucleotide sequence can comprise all or part of a gene of interest, as well as other sequences not necessarily associated with any known gene. Optionally, for ease of later recovery of the gene of interest (in "activated" or modified form), the first DNA can optionally contain a second FLP recombination target site.

The second DNA employed in the practice of the present invention is selected from at least a second portion of the first gene of interest or at least a portion of a second gene of interest (including an intact form of a second gene of interest). When the second DNA is at least a second portion of the first gene of interest, the site-specific recombination of the present invention may act to provide a functional combination of the different portions of the first gene of interest. Alternatively, when the second DNA is at least a portion of a second gene of interest, the site-specific recombination of the present invention may act to provide a functional hybrid gene, which produces a product which is not identical with either the product of the first gene or the second gene. As yet another alternative, when the second DNA is a portion of a second gene, the site-specific recombination of the present invention may act to disrupt the function of the first gene of interest. Based on the nature of the first DNA and the second DNA, as well as the mode of interaction between the two, the site-specific interaction of the present invention may create or disrupt a feature which is colorimetrically detectable, immunologically detectable, genetically detectable, and the like.

In accordance with the present invention, assembly of a functional expression unit is achieved in any of a variety of ways, e.g., by association of the gene of interest with a functional promoter, by assembly of common gene fragments to produce a complete functional gene (which, in combination with its promoter, comprises a functional expression unit), or assembly of diverse gene fragments from diverse sources to produce a functional, hybrid gene (which, in combination with a promoter, comprises a functional expression unit), and the like. Upon assembly of a functional expression unit as described herein, expression of the functional gene to produce a protein product can be activated in the usual manner. In the absence of FLP-mediated recombination, activation of expression would fail to produce a functional protein product.

In accordance with the present invention, dis-assembly of a functional expression unit is achieved in any of a variety of ways, e.g., by dis-associating the gene of interest from a functional promoter, by dis-assembly (e.g., disruption) of the functional gene (e.g., by introduction of DNA which renders the entire sequence non-functional), by removal of a substantial portion of the coding region of said gene, and the like. Upon dis-assembly of a functional expression unit as described herein, expression of the functional gene product under the conditions required prior to gene dis-assembly is no longer possible. The ability of the expression unit to be activated for expression has therefore been disrupted. The gene in this situation can be said to be inactivated, since activation of expression is not possible.

Individually inactive gene segments contemplated for use in the practice of the present invention are fragments which, alone, do not encode functional products. Such fragments can be derived from a first gene of interest alone, or from both a first and second gene of interest DNA fragments.

When gene inactivation is desired, the gene of interest can be disrupted with a DNA fragment which throws the gene of interest out of reading frame (e.g., an insert wherein the number of nucleotides is not a multiple of 3). Alternatively, the gene of interest can be disrupted with a fragment which encodes a segment which is substantially dissimilar with the gene of interest so as to render the resulting product non-functional. As yet another alternative, the gene of interest can be disrupted so as to dis-associate the gene of interest from the transcriptional control of the promoter with which it is normally associated.

The introduction of DNA, e.g., DNA encoding FLP recombination target sites, into the genome of target cells can be accomplished employing standard techniques, e.g., transfection, microinjection, electroporation, infection with retroviral vectors, and the like.

Introduction of protein, e.g., FLP recombinase protein, to host cells and/or organisms can be accomplished by standard techniques, such as for example, injection or microinjection, transfection with nucleotide sequences encoding FLP, and the like.

When employed for gene therapy of an intact organism, introduction of transgenic cells into the subject is accomplished by standard techniques, such as for example, grafting, implantation, and the like.

Mammalian cells contemplated for use in the practice of the present invention include all members of the order Mammalia, such as, for example, human cells, mouse cells, rat cells, monkey cells, hamster cells, and the like.

Host organisms contemplated for use in the practice of the present invention include each of the organism types mentioned above, with the proviso, however, that no claim is made to genetically modified human hosts (although the present invention contemplates methods for the treatment of humans).

Once FLP recombinase (or DNA encoding same) and DNA containing at least one FLP recombination target site have been introduced into suitable host cells/organisms, the cells/host organisms are maintained under conditions suitable for the site-specific recombination of DNA. Such conditions generally involve conditions required for the viability of the host cell or organism. For in vitro manipulations, conditions employed typically involve low concentrations of a variety of buffers having a pH of between about 5-9 and ionic strengths in the range of about 50-350 mM. See, for example, Senecoff, et al., in Journal of Molecular Biology, Vol. 201: 405-421 (1988).

In accordance with a particular aspect of the present invention, a co-transfection assay has been developed which can be used to characterize FLP-mediated recombination of extrachromosomal DNA in a variety of cell lines. Cells are co-transfected with an expression construct and a "reporter" plasmid that is a substrate for the recombinase. The expression construct encodes a FLP recombinase protein. The reporter plasmid encodes either a functional reporter gene containing at least one recombination target site therein, or a non-functional reporter gene containing at least one recombination target site therein. Upon expression of FLP by the expression construct, the functional reporter gene will be rendered non-functional, or the non-functional reporter gene will be rendered functional. Thus, the activity of the expression construct can be assayed either by recovering the reporter plasmid and looking for evidence of recombination at the DNA level, or by preparing cytoplasmic extracts and looking for evidence of recombination at the protein level (i.e., by measuring the expression of reporter gene activity generated by the recombined reporter). Such assays are described in greater detail in Example 1 below.

The invention will now be described in greater detail by reference to the following non-limiting examples.

EXAMPLES Example 1

Co-transfection Assays.

The co-transfection assay used to characterize FLP-mediated recombination of extrachromosomal DNA involved transfection of cells with an expression construct and a "reporter" plasmid that was a substrate for the recombinase. The activity of the expression construct could be assayed either by recovering the reporter plasmid and looking for molecular evidence of recombination at the DNA level, or by preparing cytoplasmic extracts and looking for evidence of recombination at the protein level (i.e., by measuring β-galactosidase activity generated by recombined reporter).

The pNEOβGAL reporter plasmid used for these assays was derived from pFRTβGAL (FIG. 2A). In the Figure, half-arrows indicate positions of FLP recombination target (FRT) sites; E and S designate EcoRI and ScaI restriction sites, respectively; Psv designates early promoter from SV40; BETA-GAL designates the β-galactosidase structural sequence; NEO designates neomycin expression cassette; Pcmv designates the cytomegalovirus immediate early promoter; IN designates an intron; FLP designates a FLP coding sequence; AN designates an SV40 adenylation cassette; thin lines represent vector sequences; and the sizes of restriction fragments are indicated in kb.

pFRTβGAL contains a version of the bacterial β-galactosidase sequence modified by insertion of a FLP recombination target site, or FRT, within the protein coding sequence immediately 3' to the translational start. The oligonucleotide used for the construction of pFTβRGAL was: ##STR2## This oligonucleotide contains an in-frame start codon, minimal FRT site, and an additional copy of the 13-bp FRT repeat °XXX°!; the XbaI site within the FRT spacer is enclosed in parentheses. The linker was inserted between the BamHI and HindIII sites of pSKS105 (M. J. Casadaban, A. Martin-Arias, S. K. Shapira, and J. Chou, Meth Enzymol. 100, 293 (1983)) and the LacZ portion of modified gene was cloned into a pSV2 vector. The neomycin cassette used for construction of pNEOβGAL was an XhoI to BamHI fragment from pMClneo-polyA (K. Thomas and M. Capecchi, Cell 51: 503 (1987)) cloned between copies of the J3 FRT site in pUC19.

The FRT consists of two inverted 13-base-pair (bp) repeats and an 8-bp spacer that together comprise the minimal FRT site, plus an additional 13-bp repeat which may augment reactivity of the minimal substrate. The β-galactosidase translational reading frame was preserved upon insertion of the FRT site, and the resulting plasmid, pFRTβGAL, generated robust activity in mammalian cells (Table 1).

pNEOβGAL was constructed by cutting pFRTβGAL in the middle of the FRT site with XbaI and then inserting an XbaI fragment consisting of two half-FRT sites flanking a neomycin transcription unit. This created intact FRTs on either side of the neomycin cassette and rendered the β-galactosidase transcription unit inactive (Table 1). Precise FLP-mediated recombination of the FRTs caused the excission of the neomycin cassette, recreated the parental pFRTβGAL plasmid, and restored β-galactosidase expression.

Co-transfection of cells with a fixed amount of pNEOβGAL reporter plasmid and increasing amounts of the pOG44 FLP expression vector generated increasing amounts of recombined reporter plasmid and consequently, increased levels of β-galactosidase activity. Molecular evidence for FLP-mediated recombination was obtained by recovering plasmids 36 hours after transfection, followed by endonuclease treatment (with EcoRI and ScaI) and Southern blotting (see FIG. 2B; employing as a probe the fragment of pFRTβGAL indicated at the top of FIG. 2A). Lysates of cells from cotransfections that included the pOG44 FLP expression vector showed a signal at 5.6 kb, the position at which recombined reporter (equivalent to pFRTβGAL) would run, and a 3.2 kb signal that was generated by unrecombined pNEOβGAL reporter (FIG. 2A). The 5.6 kb band intensity was proportional to the amount of FLP expression plasmid included in the transfection. The 5.6 kb band was not seen in cotransfections in which a non-FLP plasmid was substituted for the FLP expression vector (FIG. 2B) or in transfections that contained only pOG44 (and no reporter plasmid). pOG44 generated additional signals at 2.2 kb and 2.8 kb because the plasmid used in its construction contained EcoRI and EcoRI-ScaI fragments of such length.

pOG44 consists of the cytomegalovirus immediate early promoter from pCDM8 see Aruffo and Seed in Proc. Natl Acad. Sci. , USA 84: 8573 (1987)!, a 5' leader sequence and synthetic intron from pMLSIScat see Huang and Gorman in Nucl. Acids Res. 18: 937 (1990)!, the FLP coding sequence (bp 5568-6318 and 1-626 of the 2 μm circle, see Hartley and Donelson, Nature 286: 860 (1980)! and the SV40 late region polyadenylation signal from pMLSIScat. The following silent nucleotide substitutions were introduced into the structural FLP sequence using the polymerase chain reaction: C for T at position 5791, G for A at 5794, G for C at 5800, C for T at 55, G for A at 58, and C for T at 103. These changes eliminated three cannonical AATAAA polyadenylation signals and introduced a PstI restriction site without altering the amino acid sequence encoded by the nucleotide sequence. pOG28 consists of a murine cDNA for dihydrofolate reductase cloned into pCDM8 (Aruffo and Seed, supra).

In the same samples, β-galactosidase activity was also proportional to the amount of FLP expression plasmid included (FIG. 2C). Only background activities were observed in cotransfections that included a non-FLP control plasmid (Table 1) or when pOG44 alone was transfected. The experiment thus provides both molecular and biochemical evidence for precise FLP-mediated recombination in mammalian cells.

Table 1 presents β-galactosidase activities in cotransfection assays of 293, CV-1, and F-9 cells. Positive control transfections (pFRTβGAL) included 1 μg of pFRTβGAL and 18 μg of the pOG28 non-FLP control plasmid; negative control transfections (pNEOβGAL) included 1 μg of pNEOβGAL and 18 μg of the pOG28; and experimental transfections (pNEOβGAL+FLP) contained 1 μg of pNEOβGAL and 18 μg of the pOG44 FLP expression plasmid (FIG. 1A). The column headed by "%" shows the pNEOβGAL+FLP values as a percentage of the pFRTβGAL positive control. Each value represents the mean for six plates from two experiments. Standard errors are in parentheses. Neither pOG28 nor pOG44 generated β-galactosidase activity when transfected alone. All transfections contained 1 μg of pRSVL de Wet et al., Mol. Cell. Biol. 7: 725 (1987)! to correct β-galactosidase activities for relative transfection efficiencies.

Subconfluent cultures of cells in 10 cm dishes and grown in Dulbecco's modified Eagle's medium (DMEM) and 5% calf serum were transfected by overnight exposure to calcium phosphate precipitates Graham et al., Virology 36: 59 (1979)! and then split 1:4. After 24 hours incubation, one plate of each transfection was harvested by Hirt extraction J. Mol Biol. 26: 365 (1967)! and a second plate was used to prepare cytoplasmic extracts de Wet et al., supra!. Approximately 5% of the DNA recovered from single plates was used for Southern analyses. β-galactosidase assays were performed as described by Hall et al., in J. Mol. Appl. Genet. 2: 101 (1983)!. Luciferase activities generated by the inclusion of 1 μg of pRSVL (de Wet et al., supra) in all transfections were used to correct β-galactosidase activities for relative transfection efficiencies. The experiment was repeated twice with similar results.

              TABLE 1______________________________________β-GALACTOSIDASE ACTIVITIES (UNITS/MG PROTEIN)IN COTRANSFECTED CELLSTRANSFECTIONS                         pNEOβGAL +CELL LINE   pFRTβGAL              pNEOβGAL                         FLP      %______________________________________293     30.4 (1.9) 0.17 (0.02)                         14.2 (2.2)                                  47CV-1    275 (25)   0.33 (0.06)                         22.6 (1.2)                                  8F9      24.8 (4.3) 0.04 (0.01)                         1.88 (0.02)                                  8______________________________________

FLP activity has also been demonstrated in monkey kidney (CV-1) and mouse embryonal carcinoma (F9) cells. In Table 1, the β-galactosidase activity in the "pFRTβGAL" transfections represents an estimate of the expression expected if all the pNEOβGAL in a co-transfection were immediately recombined. The highest β-galactosidase expression in co-transfections employing pNEOβGAL plus pOG44, relative to pFRTβGAL transfected cells, was 47%, seen in 293 cells. This is a remarkable level considering that β-galactosidase expression required both FLP expression, followed by recombination of pNEOβGAL, to produce a construct capable of expressing β-galactosidase. Co-transfections of CV-1 and F9 cells generated 8% of the activity seen in the pFRTβGAL transfections. Even at this lower relative activity, cotransfected cells were readily observed in histochemical reactions for β-galactosidase activity.

Example 2

FLP-Mediated Removal of Intervening Sequences

If the invention method is to be widely applicable, for example for gene activation in transgenic mammals, the ability of FLP to faithfully promote precise recombination at FLP recombination target sites contained in the mammalian genome is required. Such ability is demonstrated in this example.

Cell lines that contain single integrated copies of pNEOβGAL (designated CVNEOβGAL/E) were produced by transfecting CV-1 cells with linearized plasmid by electroporation, then isolated by selecting G418-resistant (G418R) transfectants that stably expressed the neomycin cassette, and finally identifying single copy lines by Southern blot analyses (FIG. 3). As previously shown for other integrated constructs with similarly short direct repeats, the chromosomal FRTs did not spontaneously recombine (in the absence of FLP) to produce a β-galactosidase-positive (βGAL+) phenotype at detectable frequencies (Table 2).

Transient expression of FLP in the CVNEOβGAL/E lines (by transiently transfecting with the pOG44 FLP expression vector) promoted a rapid conversion to a βGAL+ phenotype. When five different lines were transiently transfected with the pOG44 FLP expression vector, β-galactosidase activities at 36 hours were 40 to 100-fold higher than those seen in replicate plates transfected with a non-FLP plasmid (Table 2). At 48 hours after transfection histochemical processing showed many positive cells (Table 2).

Table 2 presents the β-galactosidase phenotypes of CVNEOβGAL/E lines, which contain a single copy of the β-galactosidase inactive reporter, pNEOβGAL, after transfection with FLP expression (pOG44), non-FLP negative control (pOG28) or β-galactosidase positive control (pFRTβGAL) plasmids. The pFRTβGAL transfections included 1 μg of pFRTβGAL and 19 μg of pOG44; other mixes contained 20 μg of the indicated plasmid. β-galactosidase activities are mean values for triplicate transfections performed as described for FIG. 2 and assayed 36 hours after removal of precipitates; standard errors for the pOG44 transfections were less than 10% of the mean. The percent positive was determined by scoring more than 103 cells after transfection and histochemical processing as described by de Wet et al., supra.

              TABLE 2______________________________________β-GALACTOSIDASE PHENOTYPES OFTRANSFECTED CVNEOβGAL CELL LINES  ACTIVITIESCELL   (units/mg protein)               PERCENT POSITIVELINE  pOG28     pOG44   pOG28   pFRTβGAL                                   pOG44______________________________________E6    0.24      11.2    0†                            8.7     6.1E25   0.21      16.7    0†                           17.1    12.4E26   0.18      7.2     0†                           19.5    15.4E14   0.28      13.1    ND      ND      NDE22   0.09      9.6     ND      ND      ND______________________________________ †No positive cells were found among >106 cells examined. ND: Not done.

To provide some estimate of the efficiency of recombination, an additional set of replicate plates were transfected with the pFRTβGAL β-galactosidase expression vector. Comparing the fractions of cells that were βGAL+ in the pFRTβGAL and in the pOG44 transfections (assuming similar transfection efficiencies) suggests that most (70-80%) of the cells transfected with pOG44 were converted to a βGAL+ phenotype (Table 2). The comparison undoubtedly underestimates the efficiency of FLP-mediated excision. Whereas many copies of a functional β-galactosidase gene were available for immediate transcription in the positive controls, recombination may have occurred shortly before harvest in some pOG44-transfected cells. In these cases the single recombined reporter gene may not have generated enough β-galactosidase by the time of harvest to render the cells positive in this assay.

The βGAL+ phenotype was passed on to all descendents of many FLP-converted cells. Positive colonies were formed during prolonged expansion of individual colonies. Entirely negative colonies and mixed colonies were also observed. Mixed colonies would be expected if recombination occurred after mitosis in only one descendent of a transfected cell, or if recombined and unrecombined cells mixed at replating or during subsequent growth. Indeed, the physical segregation of phenotypes evident in most mixed colonies suggested that they were composed of stably positive and negative lineages.

The correlation between β-galactosidase expression and recombination at FRT sites was examined by comparing the structure of the integrated pNEOβGAL sequences in two βGAL+ subclones to the parental line. CVNEOβGAL/E25 (106) cells were transfected with the pOG44 FLP expression vector and subcloned 12 hours after removal of the precipitate. After histochemical screening, two βGAL+ subclones (E25B1 and E25B2) were expanded for further analysis. In Southern blots of genomic DNA from both subclones, the pattern of hybridization matched that expected for FLP-mediated recombination of the FRT sites in the parental line (FIG. 3). While recombination products have not been recovered and sequenced, these Southern analyses and the fact that activation of β-galactosidase expression required creation of a functional translational reading frame indicate that FLP-mediated recombination was precise.

Example 3

FLP Mediated Recombination of FRT on an Extrachromosomal Molecule With a Chromosomally Integrated FRT.

Reversal of the process described in the previous Example, i.e., the FLP-mediated recombination of an FRT site on a plasmid with a chromosomally integrated FRT site, can be used to target the integration of transfected plasmids to specific genomic sites. To determine the frequency at which this occurs, G418-sensitive, βGAL+ E25B2 cells were co-transfected with the pOG44 FLP expression vector and a plasmid, pOG45, that contained a neomycin resistance gene expression cassette and a single FRT. pOG45 consisted of the neomycin resistance cassette and 3' FRT from pNEOβGAL cloned into pUC19.8 8×105 CVNEOβGAL cells were transfected by electroporation in 800 μl of saline containing 40 μg of pOG44 and 0.1 μg of either pOG45 or, for a negative control, pOG45A (which was derived from pOG45 by deleting a 200 bp fragment containing the FRT).

G418R subclones (designated B2N) from three transfections that had stably integrated pOG45 were histochemically stained for β-galactosidase activity and more than half (104 of 158, or - 66%) were either entirely β-galactosidase-negative (βGAL-) or predominantly βGAL- with a few clusters of βGAL+ cells. The remaining colonies were βGAL+. With continued passage as dispersed monolayers, the fraction of βGAL+ cells in the mosaic lines rapidly diminished. This suggested they were G418- sensitive cells that initially survived because of their proximity to resistant cells; this was confirmed by reconstitution experiments. All of the 55 colonies formed after parallel co-transfections of pOG44 and a derivative of pOG45 (pOG45A) that lacked an FRT were βGAL+.

The correlation between loss of β-galactosidase activity and recombination between plasmid and chromosomal FRTs was examined in Southern analyses. Because the FRT and neomycin cassette of pOG45 were derived from the neomycin cassette and 3' FRT of pNEOβGAL (FIG. 2A), recombination of the plasmid FRT with the E25B2 chromosomal FRT regenerates the 3.2 kb EcoRI fragment of the original CVNEOβGAL/E25 parent. Additionally, the 8.5 kb junctional fragment of CVNEOβGAL/E25 shifts to 12.0 kb because pOG45 is 3.5 kb larger than the neomycin cassette of pNEOβGAL. The 3.2 kb EcoRI fragment and the 8.5 kb junctional fragment were observed in each of the 10 cell lines analyzed after initial histochemical classification as βGAL- or mosaic, as shown for two such lines in FIG. 3B. In contrast, each of the four βGAL+ colonies examined by Southern analyses showed that pOG45 had integrated at a random site.

These data show that FLP-mediated recombination will target the integration of transfected DNA to a specific chromosomal site at frequencies that exceed those of random integration, and that the event can be marked by the alteration in gene activity at the target site. The efficiency of targeted integration can be increased by standard optimization techniques, such as for example, by using ratios of the integrating plasmid and FLP expression vectors different from the single ratio mixture used here, or by using FRT mutations in the plasmid and chromosomal sites to decrease the frequency with which successfully integrated plasmids are subsequently excised.

While the invention has been described in detail with reference to certain preferred embodiments thereof, it will be understood that modifications and variations are within the spirit and scope of that which is described and claimed.

SUMMARY OF SEQUENCES

Sequence I.D. No. 1 is the approximately 1450 base-pair sequence encoding a FLP recombinase contemplated for use in the practice of the present invention, as well as the amino acid sequence deduced therefrom.

Sequence I.D. No. 2 is the amino acid sequence deduced from the nucleotide sequence of Sequence ID No. 1.

Sequence I.D. No. 3 is the nucleotide sequence of the FLP recombination target site (FRT).

Sequence I.D. No. 4 is the nucleotide sequence of the oligonucleotide used in the construction of pFTβRGAL.

__________________________________________________________________________SEQUENCE LISTING(1) GENERAL INFORMATION:(iii) NUMBER OF SEQUENCES: 4(2) INFORMATION FOR SEQ ID NO:1:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 1380 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(vii) IMMEDIATE SOURCE:(B) CLONE: NATIVE FLP(ix) FEATURE:(A) NAME/KEY: CDS(B) LOCATION: 1..1269(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:ATGCCACAATTTGATATATTATGTAAAACACCACCTAAGGTGCTTGTT48MetProGlnPheAspIleLeuCysLysThrProProLysValLeuVal151015CGTCAGTTTGTGGAAAGGTTTGAAAGACCTTCAGGTGAGAAAATAGCA96ArgGlnPheValGluArgPheGluArgProSerGlyGluLysIleAla202530TTATGTGCTGCTGAACTAACCTATTTATGTTGGATGATTACACATAAC144LeuCysAlaAlaGluLeuThrTyrLeuCysTrpMetIleThrHisAsn354045GGAACAGCAATCAAGAGAGCCACATTCATGAGCTATAATACTATCATA192GlyThrAlaIleLysArgAlaThrPheMetSerTyrAsnThrIleIle505560AGCAATTCGCTGAGTTTCGATATTGTCAATAAATCACTCCAGTTTAAA240SerAsnSerLeuSerPheAspIleValAsnLysSerLeuGlnPheLys65707580TACAAGACGCAAAAAGCAACAATTCTGGAAGCCTCATTAAAGAAATTG288TyrLysThrGlnLysAlaThrIleLeuGluAlaSerLeuLysLysLeu859095ATTCCTGCTTGGGAATTTACAATTATTCCTTACTATGGACAAAAACAT336IleProAlaTrpGluPheThrIleIleProTyrTyrGlyGlnLysHis100105110CAATCTGATATCACTGATATTGTAAGTAGTTTGCAATTACAGTTCGAA384GlnSerAspIleThrAspIleValSerSerLeuGlnLeuGlnPheGlu115120125TCATCGGAAGAAGCAGATAAGGGAAATAGCCACAGTAAAAAAATGCTT432SerSerGluGluAlaAspLysGlyAsnSerHisSerLysLysMetLeu130135140AAAGCACTTCTAAGTGAGGGTGAAAGCATCTGGGAGATCACTGAGAAA480LysAlaLeuLeuSerGluGlyGluSerIleTrpGluIleThrGluLys145150155160ATACTAAATTCGTTTGAGTATACTTCGAGATTTACAAAAACAAAAACT528IleLeuAsnSerPheGluTyrThrSerArgPheThrLysThrLysThr165170175TTATACCAATTCCTCTTCCTAGCTACTTTCATCAATTGTGGAAGATTC576LeuTyrGlnPheLeuPheLeuAlaThrPheIleAsnCysGlyArgPhe180185190AGCGATATTAAGAACGTTGATCCGAAATCATTTAAATTAGTCCAAAAT624SerAspIleLysAsnValAspProLysSerPheLysLeuValGlnAsn195200205AAGTATCTGGGAGTAATAATCCAGTGTTTAGTGACAGAGACAAAGACA672LysTyrLeuGlyValIleIleGlnCysLeuValThrGluThrLysThr210215220AGCGTTAGTAGGCACATATACTTCTTTAGCGCAAGGGGTAGGATCGAT720SerValSerArgHisIleTyrPhePheSerAlaArgGlyArgIleAsp225230235240CCACTTGTATATTTGGATGAATTTTTGAGGAATTCTGAACCAGTCCTA768ProLeuValTyrLeuAspGluPheLeuArgAsnSerGluProValLeu245250255AAACGAGTAAATAGGACCGGCAATTCTTCAAGCAATAAACAGGAATAC816LysArgValAsnArgThrGlyAsnSerSerSerAsnLysGlnGluTyr260265270CAATTATTAAAAGATAACTTAGTCAGATCGTACAATAAAGCTTTGAAG864GlnLeuLeuLysAspAsnLeuValArgSerTyrAsnLysAlaLeuLys275280285AAAAATGCGCCTTATTCAATCTTTGCTATAAAAAATGGCCCAAAATCT912LysAsnAlaProTyrSerIlePheAlaIleLysAsnGlyProLysSer290295300CACATTGGAAGACATTTGATGACCTCATTTCTTTCAATGAAGGGCCTA960HisIleGlyArgHisLeuMetThrSerPheLeuSerMetLysGlyLeu305310315320ACGGAGTTGACTAATGTTGTGGGAAATTGGAGCGATAAGCGTGCTTCT1008ThrGluLeuThrAsnValValGlyAsnTrpSerAspLysArgAlaSer325330335GCCGTGGCCAGGACAACGTATACTCATCAGATAACAGCAATACCTGAT1056AlaValAlaArgThrThrTyrThrHisGlnIleThrAlaIleProAsp340345350CACTACTTCGCACTAGTTTCTCGGTACTATGCATATGATCCAATATCA1104HisTyrPheAlaLeuValSerArgTyrTyrAlaTyrAspProIleSer355360365AAGGAAATGATAGCATTGAAGGATGAGACTAATCCAATTGAGGAGTGG1152LysGluMetIleAlaLeuLysAspGluThrAsnProIleGluGluTrp370375380CAGCATATAGAACAGCTAAAGGGTAGTGCTGAAGGAAGCATACGATAC1200GlnHisIleGluGlnLeuLysGlySerAlaGluGlySerIleArgTyr385390395400CCCGCATGGAATGGGATAATATCACAGGAGGTACTAGACTACCTTTCA1248ProAlaTrpAsnGlyIleIleSerGlnGluValLeuAspTyrLeuSer405410415TCCTACATAAATAGACGCATATAAGTACGCATTTAAGCATAAACACGCACT1299SerTyrIleAsnArgArgIle420ATGCCGTTCTTCTCATGTATATATATATACAGGCAACACGCAGATATAGGTGCGACGTGA1359ACAGTGAGCTGTATGTGCGCA1380(2) INFORMATION FOR SEQ ID NO:2:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 423 amino acids(B) TYPE: amino acid(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:MetProGlnPheAspIleLeuCysLysThrProProLysValLeuVal151015ArgGlnPheValGluArgPheGluArgProSerGlyGluLysIleAla202530LeuCysAlaAlaGluLeuThrTyrLeuCysTrpMetIleThrHisAsn354045GlyThrAlaIleLysArgAlaThrPheMetSerTyrAsnThrIleIle505560SerAsnSerLeuSerPheAspIleValAsnLysSerLeuGlnPheLys65707580TyrLysThrGlnLysAlaThrIleLeuGluAlaSerLeuLysLysLeu859095IleProAlaTrpGluPheThrIleIleProTyrTyrGlyGlnLysHis100105110GlnSerAspIleThrAspIleValSerSerLeuGlnLeuGlnPheGlu115120125SerSerGluGluAlaAspLysGlyAsnSerHisSerLysLysMetLeu130135140LysAlaLeuLeuSerGluGlyGluSerIleTrpGluIleThrGluLys145150155160IleLeuAsnSerPheGluTyrThrSerArgPheThrLysThrLysThr165170175LeuTyrGlnPheLeuPheLeuAlaThrPheIleAsnCysGlyArgPhe180185190SerAspIleLysAsnValAspProLysSerPheLysLeuValGlnAsn195200205LysTyrLeuGlyValIleIleGlnCysLeuValThrGluThrLysThr210215220SerValSerArgHisIleTyrPhePheSerAlaArgGlyArgIleAsp225230235240ProLeuValTyrLeuAspGluPheLeuArgAsnSerGluProValLeu245250255LysArgValAsnArgThrGlyAsnSerSerSerAsnLysGlnGluTyr260265270GlnLeuLeuLysAspAsnLeuValArgSerTyrAsnLysAlaLeuLys275280285LysAsnAlaProTyrSerIlePheAlaIleLysAsnGlyProLysSer290295300HisIleGlyArgHisLeuMetThrSerPheLeuSerMetLysGlyLeu305310315320ThrGluLeuThrAsnValValGlyAsnTrpSerAspLysArgAlaSer325330335AlaValAlaArgThrThrTyrThrHisGlnIleThrAlaIleProAsp340345350HisTyrPheAlaLeuValSerArgTyrTyrAlaTyrAspProIleSer355360365LysGluMetIleAlaLeuLysAspGluThrAsnProIleGluGluTrp370375380GlnHisIleGluGlnLeuLysGlySerAlaGluGlySerIleArgTyr385390395400ProAlaTrpAsnGlyIleIleSerGlnGluValLeuAspTyrLeuSer405410415SerTyrIleAsnArgArgIle420(2) INFORMATION FOR SEQ ID NO:3:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 34 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: unknown(D) TOPOLOGY: unknown(ii) MOLECULE TYPE: cDNA(vi) ORIGINAL SOURCE:(C) INDIVIDUAL ISOLATE: FLP recombination target site(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:GAAGTTCCTATTCTCTAGAAAGTATAGGAACTTC34(2) INFORMATION FOR SEQ ID NO:4:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 68 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: unknown(D) TOPOLOGY: unknown(ii) MOLECULE TYPE: cDNA(vi) ORIGINAL SOURCE:(C) INDIVIDUAL ISOLATE: Synthetic oligonucleotide(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:GATCCCGGGCTACCATGGAGAAGTTCCTATTCCGAAGTTCCTATTCTCTAGAAAGTATAG60GAACTTCA68__________________________________________________________________________
Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US4959317 *Apr 29, 1987Sep 25, 1990E. I. Du Pont De Nemours And CompanySite-specific recombination of DNA in eukaryotic cells
US4997757 *May 12, 1988Mar 5, 1991Genebiomed, Inc.Saccharomyces
Non-Patent Citations
Reference
1 *Golic et al. 1989. Cell. 59, 499 509.
2Golic et al. 1989. Cell. 59, 499-509.
3 *Houdebine, L. M. 1994. J. Biotechmol. 34, 269 287.
4Houdebine, L.-M. 1994. J. Biotechmol. 34, 269-287.
5 *Palmiter, R.D. 1986 Ann. Rev. Genet. 20, 465 499.
6Palmiter, R.D. 1986 Ann. Rev. Genet. 20, 465-499.
7 *Senecoff et al. 1985. Proc. Natl. Acad. Sci USA 82, 7270 7274.
8Senecoff et al. 1985. Proc. Natl. Acad. Sci USA 82, 7270-7274.
9 *Wall, R.J. 1996. Theriogenology 45. 57 68.
10Wall, R.J. 1996. Theriogenology 45. 57-68.
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US5885836 *Apr 8, 1997Mar 23, 1999The Salk Institute For Biological StudiesFLP-mediated gene modification in mammalian cells, and compositions and cells useful therefor
US6143557 *Jan 20, 1999Nov 7, 2000Life Technologies, Inc.Recombination cloning using engineered recombination sites
US6171861Jan 12, 1998Jan 9, 2001Life Technologies, Inc.Recombinational cloning using engineered recombination sites
US6175058Mar 5, 1999Jan 16, 2001Pioneer Hi-Bred International, Inc.Nucleotide sequence having maize-preferred codons; for transformed plants allowing efficient site-directed recombination
US6187994Nov 17, 1998Feb 13, 2001Pioneer Hi-Bred International, Inc.Compositions and methods for genetic modification of plants
US6262341Nov 17, 1998Jul 17, 2001Pioneer Hi-Bred International, Inc.Method for the integration of foreign DNA into eukaryotic genomes
US6270969 *Jan 20, 1999Aug 7, 2001Invitrogen CorporationRecombinational cloning using engineered recombination sites
US6277608Apr 22, 1999Aug 21, 2001Invitrogen CorporationCloning target nucleotide sequences; mixing expression vector and target nucleotide sequences, incubate with recombinase, amplify and recover target sequences
US6300545Nov 17, 1998Oct 9, 2001Pioneer Hi-Bred International, Inc.Transferring microorganismal replicon from agrobacterium to cell; providing replicon, infect cell of plant, monitor plant genome for insertion of replicon
US6331661Nov 17, 1998Dec 18, 2001Pioneer Hi-Bred International, Inc.Method for directional stable transformation of eukaryotic cells
US6333318May 14, 1998Dec 25, 2001The Salk Institute For Biological StudiesUsed in therapy; for delivering recombinant proteins into a variety of cells within a patient
US6410329May 18, 2000Jun 25, 2002Novartis Finance CorporationMethod for achieving site specific integration of exogenous DNA delivered by non-biological means to plant cells
US6455315Nov 12, 1999Sep 24, 2002Pioneer Hi-Bred International, Inc.Compositions and methods to stack multiple nucleotide sequences of interest in the genome of a plant
US6458594Nov 12, 1999Oct 1, 2002Pioneer Hi-Bred International, Inc.Compositions and methods for the targeted removal of a nucleotide sequence from the genome of a plant
US6541231Oct 12, 1999Apr 1, 2003Pioneer Hi-Bred International, Inc.A recombinant protein comprising two fused site-specific recombinases; use in the construction of stably transformed plant cells; avoids excision reactions
US6552248Nov 12, 1999Apr 22, 2003Pioneer Hi-Bred International, Inc.Transforming plant with target site comprising nucleotide sequence operably linked to promoter, target site is flanked by non-identical recombination sites; locating preferred integration site by selecting plant expressing nucleotide
US6573425Nov 12, 1999Jun 3, 2003Pioneer Hi-Bred International, Inc.Compositions and methods to reduce the complexity of transgene integration in the genome of a plant
US6624297Dec 6, 1999Sep 23, 2003Pioneer Hi-Bred International, Inc.Compositions for the genetic modification of plants
US6664108Oct 1, 1999Dec 16, 2003Pioneer Hi-Bred International, Inc.Mobilization of viral genomes from T-DNA using site-specific recombination systems
US6720140Feb 4, 2000Apr 13, 2004Invitrogen CorporationRecombinational cloning using engineered recombination sites
US6720475Aug 17, 2000Apr 13, 2004Pioneer Hi-Bred International, Inc.Stable, transformed maize plants harboring a gene encoding flp or harboring frt nucleic acid sequences enable efficient site-directed recombination of nucleic acid sequences in a monocot's genome.
US6730822Oct 16, 1998May 4, 2004Avigenics, Inc.For introduction and expression of exogenous genetic material in eggs; making exogenous interferon-alpha and erythrpoietin
US6828093Jul 24, 1998Dec 7, 2004Baylor College Of MedicineRapid subcloning using site-specific recombination
US6890726 *Apr 6, 2000May 10, 2005Oklahoma Medical Research FoundationMethod for selecting recombinase variants with altered specificity
US6964861Nov 12, 1999Nov 15, 2005Invitrogen CorporationEnhanced in vitro recombinational cloning of using ribosomal proteins
US6977178Sep 3, 2002Dec 20, 2005Transnetyx, Inc.System and method for transgenic and targeted mutagenesis screening
US7011943Sep 4, 2001Mar 14, 2006Transnetyx, Inc.Detecting preferential nucleotide sequences in pool of sequences; obtain nucleotide sequences, deposit on substrate, incubate with probe, detect signal, which indicates, presencec of preferential sequences
US7045315Sep 7, 2001May 16, 2006The Salk Institute For Biological StudiesMethods for modulating expression of exogenous genes in mammalian systems
US7074983Nov 16, 2001Jul 11, 2006Kirin Beer Kabushiki KaishaTrangenic cell for use in human therapeutics and diagnostics
US7102055Dec 6, 1999Sep 5, 2006Pioneer Hi-Bred International, Inc.Compositions and methods for the targeted insertion of a nucleotide sequence of interest into the genome of a plant
US7129390Jan 24, 2003Oct 31, 2006Avigenics, IncA vector containing a coding sequence and a promoter to express such sequence in an avian oviduct, and the sequence is either recombinant transgenic poultry derived interferon-alpha 2b or erythropoietin coding sequence
US7179599May 23, 2003Feb 20, 2007Pioneer Hi-Bred International, Inc.Mobilization of viral genomes from T-DNA using site-specific recombination systems
US7198924Mar 4, 2004Apr 3, 2007Invitrogen CorporationMethods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US7223576Mar 10, 2004May 29, 2007Invitrogen CorporationExpression vector which utilizes site specific recombinases as insertion tools during in vivo and/or in vitro gene transfer
US7223601Jan 29, 2003May 29, 2007Pioneer Hi-Bred International, Inc.Genetic engineered protein
US7244560Dec 7, 2001Jul 17, 2007Invitrogen CorporationMethods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US7253334Dec 21, 2001Aug 7, 2007Aurox, LlcMethods for cloning non-human mammals using reprogrammed donor chromatin or donor cells
US7282326 *Jan 30, 2002Oct 16, 2007Invitrogen CorporationRecombinational cloning using engineered recombination sites
US7282361Mar 8, 2005Oct 16, 2007Transnetyx, Inc.Treating mammalian tissue with a lysis buffer of proteinase K to obtain a lysate, binding genomic DNA to magnetic particles in the presence of the lysate, and disassociating the DNA from the magnetic particles
US7304130Nov 2, 1999Dec 4, 2007Invitrogen CorporationVector for use as a propagation tool in genetic engineering
US7338654Mar 8, 2006Mar 4, 2008Avigenics, Inc.Glycosylated interferon alpha obtained from a transgenic chicken
US7351578Aug 14, 2003Apr 1, 2008Invitrogen Corp.Microarray comprising two or more immobilized vectors for use as replication and gene transfer tools; simultaneous cloning of two or more nucleotide sequences
US7361508May 16, 2003Apr 22, 2008Pioneer Hi-Bred International, Inc.Compositions and methods for the targeted insertion of a nucleotide sequence of interest into the genome of a plant
US7364902Apr 7, 2006Apr 29, 2008Pioneer Hi-Bred International, Inc,Mobilization of viral genomes from T-DNA using site-specific recombination systems
US7393632Dec 11, 2000Jul 1, 2008Invitrogen Corp.Use of multiple recombination sites with unique specificity in recombinational cloning
US7405079May 7, 2003Jul 29, 2008Pioneer Hi-Bred International, Inc.Nucleotide sequences; transfer cassettes; controlling gene expression; insertion of transfer cassettes
US7408049Jul 19, 2004Aug 5, 2008Invitrogen CorporationExpression vector comprising topisomerase site-specific recombination sequences for use as gene transfer and propagation tools in bioreactors; gene therapy; protein and gene expression analysis
US7414170May 19, 2003Aug 19, 2008Kirin Beer Kabushiki KaishaTransgenic bovines capable of human antibody production
US7420099Apr 21, 2005Sep 2, 2008Kirin Holdings Kabushiki KaishaTransgenic animals and uses thereof
US7429690Nov 10, 2003Sep 30, 2008Kirin Holdings Kabushiki KaishaCloned cattle comprising mutations in galactosyltransferase gene sequences which enhanced resistance to bovine spongiform encephalopy; ehancing food safety and quality
US7445774Feb 28, 2006Nov 4, 2008Avigenics, Inc.Glycosylated interferon α
US7462766May 4, 2006Dec 9, 2008Pioneer Hi-Bred International, Inc.Compositions comprising non-identical recombination sites
US7491534Apr 30, 2003Feb 17, 2009Kirin Holdings Kabushiki KaishaUsing t-cell receptor (TCR) for diagnosis and treat of immunological, autoimmune, inflammatory, cancer, infectious and eating disorders
US7491867Dec 1, 2005Feb 17, 2009Kyowa Hakko Kirin Co., Ltd.Expression of xenogenous (human) immunoglobulins in cloned, transgenic ungulates
US7494817Jun 30, 2005Feb 24, 2009Transnet Yx, Inc.Mixing cellular debris and magnetically-responsive particles (having glass microfiber coating) to facilitate reversible immobilization of genomic nucleic acid; bioassay
US7511120Feb 20, 2007Mar 31, 2009Synageva Biopharma Corp.Granulocyte colony stimulating factor obtained from eggs laid by transgenic avians having newly described G-CSF glycosylation patterns; gene expression of exogenous proteins
US7521591Oct 28, 2003Apr 21, 2009Synageva Biopharm Corp.Transgenic chickens that lay eggs containing exogenous proteins
US7534929Apr 6, 2005May 19, 2009Synageva Biopharma Corp.Avians expressing heterologous protein
US7544854Apr 18, 2002Jun 9, 2009Gene Stream Pty LimitedAnimal models; drug screening; uridine diphospho-glucuronosyl transferase; predicting likely behaviour of a drug in a selected species of primate
US7560622Oct 1, 2001Jul 14, 2009Pioneer Hi-Bred International, Inc.Generating transgenic plant; obtain cell, transform, propagate, monitor gene expression
US7572634May 7, 2003Aug 11, 2009Pioneer Hi-Bred International, Inc.Identifying specific sites of gene insertion along plant chromosomes; gene expression/transfer; transformation
US7670823Mar 2, 2000Mar 2, 2010Life Technologies Corp.Compositions for use in recombinational cloning of nucleic acids
US7736895Aug 2, 2004Jun 15, 2010Kyowa Hakko Kirin Co., Ltd.Altering differentiated state of somatic cells via adjusting gene expression patterns; removing suppressor protein from chromatin masses; reprogramming differentiated cells
US7781643Apr 13, 2009Aug 24, 2010Gene Stream Pty LimitedAnimal model comprising in its genome a homozygous disruption of an endogenous mouse multidrug-resistance-1 (MDR-1) gene ; drug screening; pharmacokinetics and pharmacodynamics; predicting likely behaviour of a drug in mouse
US7803362Jul 3, 2008Sep 28, 2010Synageva Biopharma Corp.Glycosylated with galactose-N-acetylgalactosamine; used for the introduction of exogenous nucleic acid sequences into the genome of avians in order to express the exogenous sequences to alter the phenotype of the avians or to produce desired proteins
US7803981Jun 20, 2007Sep 28, 2010Kyowa Hakko Kirin Co., Ltd.Chimeric cells coding heterologous immunoglobulin for treatment, prevention and diagnosis of infections and cell proliferative disorders
US7807863Sep 5, 2008Oct 5, 2010Kyowa Hakko Kirin Co., Ltd.Transgenic bovine having reduced prion protein activity and uses thereof
US7807868Apr 2, 2008Oct 5, 2010Pioneer Hi-Bred International, Inc.Mobilization of viral genomes from T-DNA using site-specific recombination systems
US7812127Jun 27, 2008Oct 12, 2010Synageva Biopharma Corp.Glycosylated with galactose-N-acetylgalactosamine; used for the introduction of exogenous nucleic acid sequences into the genome of avians in order to express the exogenous sequences to alter the phenotype of the avians or to produce desired proteins
US7820878May 5, 2008Oct 26, 2010Kyowa Hakko Kirin Co., Ltd.Production of ungulates, preferably bovines that produce human immunoglobulins
US7820880Nov 6, 2008Oct 26, 2010Pioneer Hi-Bred Int'l. Inc.Compositions and methods to stack multiple nucleotide sequences of interest in the genome of a plant
US7875762Jan 23, 2006Jan 25, 2011Synageva Biopharma Corp.Method of producing an exogenous protein in the egg of a chicken
US7884054Dec 21, 2004Feb 8, 2011Amgen Inc.Methods for identifying functional antibodies
US7928285Jun 25, 2008Apr 19, 2011Kyowa Hakko Kirin Co., Ltd.Method of producing xenogenous antibodies using a bovine
US8124732Sep 18, 2009Feb 28, 2012Synageva Biopharma Corp.Composition comprising isolated human CTLA4-Fc fusion protein produced in a transgenic chicken
US8143504Oct 22, 2010Mar 27, 2012Pioneer Hi-Bred International, Inc.Compositions and methods for genetic modification of plants
US8148599Aug 20, 2010Apr 3, 2012Gene Stream Pty LimitedTransgenic non-human animals for pharmacological and toxicological studies
US8241896Dec 29, 2009Aug 14, 2012Life Technologies CorporationCompositions for use in recombinational cloning of nucelic acids
US8304233Aug 4, 2005Nov 6, 2012Poetic Genetics, LlcExpression cassette vector; polynucleotide of interest linked to a promoter, a single recombination site, and a hybrid recombination site; facilitate single step site specific recombination at an endogenous nucleic acid sequence
US8372956Oct 15, 2007Feb 12, 2013Synageva Biopharma Corp.Antibodies produced in a transgenic avian egg white
US8383399Jul 8, 2011Feb 26, 2013Synageva Biopharma Corp.Nucleic acid construct having an ovalbumin promotor
US8507749Nov 15, 2005Aug 13, 2013Synageva Biopharma Corp.Transgenic chickens producing exogenous protein in eggs
US8519214Mar 15, 2006Aug 27, 2013Synageva Biopharma Corp.Production of exogenous proteins in egg whites of transgenic chickens
US8524975Mar 9, 2012Sep 3, 2013Gene Stream Pty LimitedMethod of predicting a behavior of one or more drugs
US8536420Aug 1, 2008Sep 17, 2013Pioneer Hi-Bred International, Inc.Compositions and methods for genetic modification of plants
US8563803Jun 24, 2005Oct 22, 2013Synageva Biopharma Corp.Method of making protein in an egg of a transgenic chicken
US8603950Feb 20, 2008Dec 10, 2013Anaptysbio, Inc.Methods of generating libraries and uses thereof
US8685897May 17, 2011Apr 1, 2014Anaptysbio, Inc.Methods of generating libraries and uses thereof
US8735158Feb 28, 2008May 27, 2014Pioneer Hi-Bred International, Inc.Compositions and methods for the targeted insertion of a nucleotide sequence of interest into the genome of a plant
EP1762617A1 *Jan 7, 2004Mar 14, 2007Symphogen A/SMethod for manufacturing recombinant polyclonal proteins
EP1967529A1Jul 18, 2005Sep 10, 2008Symphogen A/SAnti-rhesus D recombinant polyclonal antibody and methods of manufacture
EP1978110A1Sep 4, 2001Oct 8, 2008Transnetyx, Inc.System, method and apparatus for transgenic and targeted mutagenesis screening
EP2314619A1Dec 4, 2006Apr 27, 2011Symphogen A/SAnti-orthopoxvirus recombinant polyclonal antibody
WO1999025841A1 *Nov 18, 1998May 27, 1999Baszczynski Christopher LNovel nucleic acid sequence encoding flp recombinase
WO2004061104A2 *Jan 7, 2004Jul 22, 2004Vincent W ColjeeMethod for manufacturing recombinant polyclonal proteins
WO2007065433A2Dec 4, 2006Jun 14, 2007Symphogen AsAnti-orthopoxvirus recombinant polyclonal antibody
WO2012033953A1Sep 8, 2011Mar 15, 2012Halozyme, Inc.Methods for assessing and identifying or evolving conditionally active therapeutic proteins
Classifications
U.S. Classification435/325, 435/354, 435/351, 435/366, 435/353, 536/24.2, 435/193, 536/24.1, 435/194, 435/363, 536/23.1, 435/197, 435/350, 435/352, 435/320.1, 536/23.74, 514/44.00R
International ClassificationC12N15/90, A01K67/027, C12N15/85, C12Q1/68, A61K38/00, C12N15/52, A61K48/00, C12N9/00
Cooperative ClassificationA61K48/00, A61K38/00, C12N15/907, C12N9/00, C12N15/85, C12N15/90, C12N2800/30, C12N15/52
European ClassificationC12N15/90, C12N15/90B4, C12N15/85, C12N9/00, C12N15/52
Legal Events
DateCodeEventDescription
Mar 25, 2009FPAYFee payment
Year of fee payment: 12
Mar 15, 2005FPAYFee payment
Year of fee payment: 8
Apr 13, 2001FPAYFee payment
Year of fee payment: 4